Mycronic AB (MYCR) AI Stock Analysis

• Market Cap: kr41.91B
• Dividend Yield: 1.75%
• Average Volume (3M): 171.55K
• Price to Earnings (P/E): 24.0
• Beta (1Y): 1.14
• Revenue Growth: 14.48%
• EPS Growth: 0.52%
• Country: SE
• Employees: 2,318
• Sector: Technology
• Sector Strength: 88
• Industry: Industrial - Machinery
• EPS (TTM): 1.11
• Shares Outstanding: 195,833,020
• 10 Day Avg. Volume: 161,326
• 30 Day Avg. Volume: 171,548
• PEG Ratio: -0.74
• Price to Book (P/B): 2.98
• Price to Sales (P/S): 2.76
• P/FCF Ratio: 11.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: kr232.00 ▲(8.41% Upside)

Mycronic AB's strong financial performance is the most significant factor, supported by robust revenue and profit growth, and a solid balance sheet. Technical analysis presents mixed signals, with no clear trend direction. Valuation is moderate, with a reasonable P/E ratio and modest dividend yield. The absence of earnings call data and corporate events does not impact the score.

Positive Factors

Revenue Growth

The significant revenue growth indicates robust demand for Mycronic's products and services, supporting long-term business expansion and market presence.

Balance Sheet Health

A low debt-to-equity ratio suggests financial stability and low financial risk, providing Mycronic with flexibility to invest in growth opportunities.

Profitability

Improved profitability reflects effective cost management and operational efficiency, which can sustain long-term financial health and shareholder value.

Negative Factors

Free Cash Flow Decline

A decline in free cash flow can limit Mycronic's ability to reinvest in its business, potentially affecting future growth and financial flexibility.

Cash Flow Pressure

Pressure on cash flow, despite overall strength, may indicate challenges in maintaining cash reserves, impacting strategic investments and operations.

Operating Cash Flow

Reduced operating cash flow can strain Mycronic's ability to fund operations and growth initiatives, potentially affecting long-term business sustainability.

Mycronic AB Business Overview & Revenue Model

Company Description

Mycronic AB (MYCR) is a Swedish company that specializes in developing and manufacturing advanced production equipment for the electronics industry. The company operates primarily in two sectors: the semiconductor and the printed circuit board (PCB) assembly markets. Mycronic's core products include high-precision mask writers for semiconductor manufacturing, as well as advanced pick-and-place systems for PCB assembly, enabling efficient and accurate electronic component placement.

How the Company Makes Money

Mycronic generates revenue through the sale of its production equipment and services to various clients in the electronics manufacturing sector. Key revenue streams include the sale of high-tech machines for semiconductor fabrication and assembly lines for PCB manufacturing. Additionally, the company earns money from service agreements, maintenance contracts, and the sale of consumables required for the operation of its equipment. Strategic partnerships with leading electronics manufacturers and ongoing investments in R&D to innovate and improve product offerings further contribute to its earnings. Furthermore, Mycronic benefits from a growing demand for advanced electronics, driven by trends such as automation, electric vehicles, and the increasing complexity of electronic devices.

Mycronic AB Financial Statement Overview

Summary

Mycronic AB exhibits strong financial health with impressive revenue and profit growth, effective cost management, and efficient operations. The balance sheet is robust with low leverage and high equity, ensuring financial stability. Cash flow is strong but shows slight pressure from declining free cash flow.

Income Statement

Mycronic AB shows strong revenue growth with a 31.54% increase from 2023 to TTM. The gross profit margin is robust at 54.0% TTM, indicating effective cost management. Net profit margin improved to 24.2%, suggesting enhanced profitability. EBIT and EBITDA margins are solid at 29.8% and 29.9% respectively, indicating efficient operations. Overall, the income statement reflects healthy growth and profitability.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.03, demonstrating conservative leverage. Return on equity is impressive at 25.7%, indicating efficient use of equity to generate profits. The equity ratio of 67.1% reflects a solid capital structure and financial stability. The balance sheet suggests low financial risk and strong shareholder value.

Cash Flow

Operating cash flow to net income ratio is healthy at 0.76, showing reliable cash generation from operations. However, free cash flow decreased by 17.8% from 2024 to TTM, primarily due to reduced operating cash flow. Despite this, the free cash flow to net income ratio remains strong at 0.74, indicating good cash conversion. Overall, cash flow performance is robust but shows slight pressure from declining free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.98B	7.06B	5.71B	5.12B	4.63B	3.88B
Gross Profit	4.21B	3.72B	2.72B	2.29B	2.28B	2.08B
EBITDA	2.25B	2.32B	1.39B	1.11B	1.20B	1.06B
Net Income	1.74B	1.68B	998.00M	741.00M	828.00M	694.00M
Balance Sheet
Total Assets	10.61B	10.41B	8.34B	7.34B	6.14B	5.32B
Cash, Cash Equivalents and Short-Term Investments	2.00B	3.01B	2.14B	1.27B	683.00M	1.30B
Total Debt	361.00M	219.00M	228.00M	270.00M	243.00M	264.00M
Total Liabilities	3.67B	3.84B	3.06B	2.64B	2.14B	1.94B
Stockholders Equity	6.90B	6.53B	5.25B	4.66B	3.96B	3.36B
Cash Flow
Free Cash Flow	897.00M	1.64B	1.41B	712.00M	908.00M	991.00M
Operating Cash Flow	1.64B	1.87B	1.61B	853.00M	998.00M	1.13B
Investing Cash Flow	-1.24B	-500.00M	-195.00M	67.00M	-1.22B	-150.00M
Financing Cash Flow	-850.00M	-552.00M	-447.00M	-382.00M	-437.00M	-288.00M

Mycronic AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 214.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MYCR, the sentiment is Neutral. The current price of 214 is below the 20-day moving average (MA) of 215.80, above the 50-day MA of 212.40, and above the 200-day MA of 206.20, indicating a neutral trend. The MACD of 1.54 indicates Positive momentum. The RSI at 47.65 is Neutral, neither overbought nor oversold. The STOCH value of 42.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:MYCR.

Mycronic AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TREL.B	73 Outperform	kr83.83B	23.63	9.56%	1.94%	2.73%	7.56%
MYCR	71 Outperform	kr41.91B	23.96	26.95%	1.75%	14.48%	0.52%
ALFA	71 Outperform	kr185.50B	22.24	20.42%	1.86%	3.54%	20.94%
ATCO.B	71 Outperform	kr754.15B	25.41	26.43%	2.08%	-2.38%	-4.00%
SAND	70 Outperform	kr356.62B	24.12	16.39%	1.95%	-1.77%	21.13%
ATCO.A	67 Neutral	kr754.15B	28.26	26.43%	1.84%	-2.38%	-4.00%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%

Mycronic AB Corporate Events

Leadership Transition at Mycronic as SVP of People & Culture Departs

Mycronic has announced that Johanna Jarl, the Senior Vice President of People & Culture, will be leaving the company by April 2026 to pursue other opportunities. The company will immediately begin the search for her successor. Under Jarl’s leadership, the HR department has become more strategic and structured, emphasizing leadership, culture, inclusion, and organizational development, which has been acknowledged by the company’s President and CEO, Anders Lindqvist.

Mycronic Secures New Order for SLX Mask Writer in Asia

Mycronic AB has secured an order for an SLX mask writer from a new customer in Asia, valued between USD 5-7 million, with net sales to be recognized in the current quarter. This order highlights the increasing demand for photomasks in the semiconductor industry and underscores Mycronic’s strategic positioning in providing modern, energy-efficient mask writers, reinforcing its role in the semiconductor manufacturing sector.

Mycronic AB Sees Strong Order Growth Amidst Sales Decline

Mycronic AB reported a 67% increase in order intake for the third quarter of 2025, driven by strong performance in its Pattern Generators and Global Technologies divisions. Despite this, net sales declined by 4% due to lower sales in Pattern Generators, impacting the EBIT margin, which fell to 15%. The company is expanding its capabilities with the acquisition of Cowin DST in South Korea, pending regulatory approval, and has relocated PCB Assembly Solutions production to enhance capacity. The US market for PCB Assembly Solutions improved, while demand from the Chinese consumer electronics industry weakened. The Global Technologies division saw strong demand in AI data center markets and aerospace & defense spending in the US.

Mycronic Secures Order for SLX Mask Writer in the US

Mycronic AB has secured an order for its SLX mask writer from an existing customer in the US, valued between USD 4-6 million, with delivery expected this quarter. The SLX mask writer addresses the growing demand for photomasks in the semiconductor industry, offering modern, energy-efficient technology that enhances performance and reliability, thus reinforcing Mycronic’s position in the market.

Mycronic Secures Order for SLX Mask Writer

Mycronic AB has secured an order for an SLX mask writer from an existing Asian customer, valued between USD 5-7 million, with delivery expected in the second quarter of 2026. This order highlights the growing demand for photomasks in the semiconductor industry and strengthens Mycronic’s market presence, as the SLX mask writer supports modernization and replacement needs with its energy-efficient technology.

Mycronic Secures Order for SLX Mask Writer in Asia

Mycronic AB has secured an order for an SLX mask writer from an existing customer in Asia, valued between USD 3-5 million. This order highlights the growing demand for photomasks in the semiconductor industry, with the SLX mask writer offering modern, energy-efficient technology. The successful completion of a qualification project at the customer’s site facilitated the transfer of ownership, underscoring Mycronic’s strong positioning in the market for semiconductor manufacturing equipment.

Mycronic Secures Major Order for Mask Writers in Asia

Mycronic AB has secured a significant order for three mask writers from an existing customer in Asia, valued between USD 48-52 million. The order includes one Prexision 8 Evo and two Prexision Lite 8 Evo mask writers, with deliveries scheduled from the second quarter of 2026 to the first quarter of 2027. This order highlights Mycronic’s strong position in the market for display photomasks and its ability to offer tailored solutions that meet both current and future customer needs.

Mycronic AB Appoints 2026 Nomination Committee

Mycronic AB has appointed its Nomination Committee for the 2026 Annual General Meeting, following the guidelines set by the 2025 meeting. The committee, representing 39.1% of votes and shares, invites shareholders to submit proposals for consideration ahead of the meeting, indicating a structured approach to stakeholder engagement.